Seres Therapeutics (MCRB) Other Non-Current Assets (2014 - 2026)

Seres Therapeutics has reported Other Non-Current Assets for 12 years, with the latest figure at $8.7 million in Q1 2026.

• Quarterly Other Non-Current Assets rose 27861.29% year-over-year to $8.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $8.7 million (up 27861.29% YoY) and the FY2025 annual result came in at $8.7 million, changed N/A from the prior year.
• Other Non-Current Assets was little changed at $8.7 million in Q1 2026 per MCRB's latest filing, from $8.7 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $41.5 million in Q2 2024 and troughed at $31000.0 in Q1 2025.
• A 5-year average of $11.2 million and a median of $8.2 million in 2022 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2025 and 2026: Other Non-Current Assets sank 99.93% in 2025, then soared 27861.29% in 2026.
• Over 5 years, Other Non-Current Assets stood at $10.5 million in 2022, then fell by 21.79% to $8.2 million in 2023, then surged by 407.23% to $41.5 million in 2024, then tumbled by 79.12% to $8.7 million in 2025, then changed by 0.0% to $8.7 million in 2026.
• According to Business Quant data, Other Non-Current Assets over the past three periods registered $8.7 million, $8.7 million, and $31000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.